AMRN Amarin Corporation plc

18.17
-0.25  -1%
Previous Close 18.42
Open 18.44
Price To Book 50.47
Market Cap 6,007,734,196
Shares 330,640,297
Volume 4,168,122
Short Ratio
Av. Daily Volume 5,261,607

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review September 28, 2019.
Vascepa
High Triglycerides With Mixed Dyslipidemia

Latest News

  1. Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences
  2. Hedge Funds Have Never Been This Bullish On Amarin Corporation plc (AMRN)
  3. Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference
  4. Amarin Stock Poised for Even More Gains
  5. Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting
  6. Amarin Corporation plc (NASDAQ:AMRN): When Will It Breakeven?
  7. Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
  8. 5 Top Stock Trades for Friday: AAPL, VEEV, DG, DLTR
  9. Amarin Rises on Priority Review for Vascepa Label Expansion
  10. 3 Top Mid-Cap Stocks to Buy Right Now
  11. Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications
  12. This Biotech Stock Rocketed Near A Buy Point On Speedy Drug Review
  13. Why Cypress Semiconductor, Amarin, and Heico Jumped Today
  14. Amarin shares soar after FDA agrees to fast-track review of its prescription strength fish oil pill for heart patients
  15. Bulls shop at this discount retailer
  16. Here's Why Amarin Soared Today
  17. Amarin's Cardiovascular Fish Oil Pill May Hit Market Sooner: FDA Accords Priority Review Designation
  18. U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication
  19. Options traders say it's hip to be Square
  20. Label Expansion to Boost Revenue Growth for Amarin’s Vascepa